Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial-Reference-Cited by-同舟云学术

Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

Published:2016-07 Issue:7 Volume:17 Page:984-993
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Planchard David,Besse Benjamin,Groen Harry J M,Souquet Pierre-Jean,Quoix Elisabeth,Baik Christina S,Barlesi Fabrice,Kim Tae Min,Mazieres Julien,Novello Silvia,Rigas James R,Upalawanna Allison,D'Amelio Anthony M,Zhang Pingkuan,Mookerjee Bijoyesh,Johnson Bruce E

Publisher

Elsevier BV

Subject

Oncology

Reference36 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

3. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

4. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

5. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT);Barlesi;Lancet,2016

Cited by 722 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study;Future Oncology;2024-09-03

2. Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil;Cancers;2024-09-03

3. Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification;JCO Precision Oncology;2024-09

4. Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study;ESMO Open;2024-09

5. Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms;Die Onkologie;2024-08-15